Nonadherence to medical therapy is a widespread and complex problem that is a significant variable in the treatment of psychiatric illness and in patients’ prognosis. More than 50% of people who have a chronic illness struggle to comply with their medication regimen—for many reasons.¹

Many variables predict poor adherence, so it cannot be expected that a single solution will solve the problem entirely.² Novel adherence technologies are available, as we discuss in this article, and more are in development.

What is nonadherence to medical therapy?
Nonadherence can be defined primarily as not taking prescribed medication in the recommended dosage or frequency, or not taking prescribed medication at all.³ Nonadherence can result in an increased risk of relapse, hospitalization, poor therapeutic response, and delayed remission and recovery.

Secondarily, non-attendance or irregular attendance at appointments with providers is a form of nonadherence that can have a negative impact on treatment outcomes.⁴

Why is medical adherence important in psychiatry?
Medication nonadherence has major consequences for psychiatric patients⁵ and for the greater health care system; it is estimated that, in the United States, the cost of nonadherence is as high as $300 billion a year.⁶ In psychiatry, the rate of nonadherence to medical therapy has been reported to be 11% to 80% of patients with schizophrenia; 12% to 64% with bipo-
Adherence to medical therapy

Clinical Point

Emotional barriers to nonadherence include a sense of losing control, denial, poor insight, beliefs about illness, and self-stigmatization.

Why are patients nonadherent?

Many variables lead to patient nonadherence (Figure 1). The most common reason is that patients simply forget to take their medication. Among psychiatric patients, other reasons are:

- lack of insight
- negative emotional reaction to taking medication
- feeling better and no longer believing that the medication is needed
- distress associated with side effects
- high cost of medication
- patient’s perception that medication won’t be effective
- concern about substance abuse
- fear of dependency
- complicated dosing regimen
- general lack of motivation

Emotional barriers to medication nonadherence are an underestimated area that can benefit greatly from the expertise and understanding of psychiatrists. These barriers include a sense of losing control, self-stigmatization, denial, poor insight, and beliefs about illness and medications.

Additional patient variables that contribute to nonadherence include:

- suboptimal health literacy
- stigma and shame about the need for psychiatric treatment
- lack of patient involvement in treatment decision-making.

Who is responsible for adherence?

Adherence to medical therapy is not the patient’s responsibility, exclusively. Rather,
it is a collection of complex components that generally includes physicians and the health care system. Because barriers to medication adherence are complex and varied, solutions to improve adherence must be multifaceted.

**Providers.** Patients’ care often is managed by multiple physicians, which can lead to communication lapses about complicated drug regimens and potential adverse effects. To assist patients in adhering to their medication regimen, physicians should recognize, and acknowledge to the patient, that many psychiatric patients have difficulty taking their medications and provide advice and information in how to address this problem.

**Families.** Likewise, it is important to educate patients and their family about the need for medication—helping the patient see that it is his (her) choice and, indeed, his direct responsibility to take his medication and improve his health. The risk–benefit balance of treatment should be explained to the patient and his family, as well as the nature of the psychiatric diagnosis and how effective patient–physician collaboration can help him function and adhere to his medication regimen in a consistent, reliable manner.

**The larger system.** Health care systems can contribute to medication adherence by reducing time constraints on visits to providers, to allow time to discuss all aspects of medication adherence. Limited visits in the clinic means physicians are not able to (1) spend adequate time discussing the medication regimen to ensure full patient comprehension and (2) conduct an assessment of medication-taking behaviors.

Team-based approaches could improve efficiency, patient understanding, adherence, and early detection of adherence issues. Strategies such as additional clinic visits and reminder calls to discuss adherence carry a cost, but their long-term advantage is that, if patients understand how to better adhere to their medication regimens, their actions will have a positive impact on their health care costs and outcomes and on the wider health economy—as a result of reduced hospital admissions and reduced need to care for patients whose condition deteriorates because of nonadherence. It is imperative that we build strong relationships with other providers to show that we are committed to building supportive, effective adherence support programs that focus on the individual patient’s needs.

**What is the available technology?** There is no standard way to measure nonadherence. The most common, and simplest, measure—asking the patient—is unreliable and severely overestimates adherence.

**Direct measures of adherence** include observing the patient taking his medications and testing for the concentration of those medications in blood or urine. Indirect adherence assessment methods, such as pill counts, a medication diary, self-report, clinician ratings, pharmacy chart review, and electronic devices that monitor the opening of a lid or tablet strip, have all been used; yet reviews of those methods have shown less than favorable results. Pre-packaged pill packs have helped some patients with a simple method for medication management.

Electronic monitoring, using a medication vial cap device (Figure 2) that electronically records the date and time of bottle opening, has become common in general medicine and among patients with schizophrenia. Diaz et al reported that electronic monitoring detected a greater nonadherence rate (57%) than what prescribers reported (7%) or patients self-reported (5%)—demonstrating that prescribers and patients grossly overestimate adherence. In another study that
looked at electronic monitoring, researchers reported that adherence was much higher in depressed youth (87%) than what had been seen in adults (67%) in a similar study. The downside to pill packs and electronic monitoring? There is no guarantee the patient has actually taken the medication despite the data reported by the system.

**Event marker-signaling devices.** Novel technologies have been developed to measure adherence:

**Proteus Digital Health feedback system** (www.proteus.com) requires that patients ingest a tablet containing a tiny, dietary mineral-based “ingestible event marker.” Upon contact with gastric fluid electrolytes, the event marker emits a unique signal that is transmitted through bodily tissue to a small receiver in a patch worn on the torso. The receiver then transmits a signal to a cellular phone, indicating the time and date when the medication was ingested (Figure 3).

A 4-week pilot study found that the ingestible event marker is feasible and acceptable to patients: 27 of 28 participants (96%) completed the study, with a mean adherence rate of 74%. Although the system identifies ingestible sensors with high accuracy and is easily tolerated by patients, the pilot study was brief; a longer duration of adherence while wearing the patch needs to be studied.

**Breath analysis, facial recognition.** Even directly observing ingestion of a medication can be problematic: Some patients don’t swallow the medication and spit it out later. One way around that subterfuge is to consider using other advanced medication adherence solutions that are breath-based or use facial recognition technology and confirm ingestion.

**Xhale SMART** (www.xhale.com/smart) is a handheld device that generates a reminder to the patient to take his medication; afterward, he (she) must blow into the device so that ingestion of the medication is detected (Figure 4). The medication has breath-detectable adherence markers already incorporated. The adherence marker then is released into the stomach and small intestine, where the adherence marker metabolite is transported through the bloodstream into the lungs and exhaled. The patient must breathe into a breath analysis device, which measures medication ingestion compared with a baseline breath print. Several articles in the literature have reported the accuracy of this device in detecting the ingested metabolite in every participant, without adverse effects.

**AiCure** (www.aiicure.com) is a facial recognition-based technology platform that can work through any smartphone. The device is powered by artificial intelligence...
Comprehensive integration of novel technologies with clinical oversight, behavioral support, and patient motivation

- Oversight of medication intake and vital signs
- Risk modification and behavioral coaching
- Educational instruction on condition, treatment, and lifestyle

• Optimized provider–patient relationship
• Positive reinforcement techniques
• Reminders by text or e-mail

Therapeutic oversight and behavioral support

Intergrating digital adherence technologies

- Interactive facial recognition and motion-sensing technology
- Intelligent pill containers
- Ingestible marker tracking

Engage and empower the patient

Novel adherence technologies are, as we’ve described, available, and more are being developed. Incorporating these technologies into clinical care requires continued input and support from clinicians and patients. Digital and mobile health applications are multi-beneficial: They can empower patients to self-manage medication regimens and appointments while they also receive social and psychological information and support as needed. Understanding one’s own illness can, ultimately, improve outcomes and significantly reduce health care costs.

Patient empowerment is key. The physician is an important influencer in this regard.

The role of the physician must not be under-valued in maintaining adherence to therapy; she (he) plays a vital role in continued patient engagement and behavioral training. Integrating physician-led oversight, patient education, and commitment, and novel digital mobile adherence technologies will help deliver better outcomes.

The push to engage. A “one size fits all” approach to maintaining adherence won’t be effective. We need to better understand the individual patient’s underlying cause(s) for nonadherence, then to tailor a solution

Continued on page 36
Adherence to medical therapy

**Clinical Point**

The relationship between patient and physician, and the therapeutic alliance, are key to optimal adherence to a medical regimen.

**Related Resources**


**Drug Brand Name**

Aripiprazole - Abilify

Nonadherence to medical therapy is a large and detrimental phenomenon across medicine, but especially among people suffering from a brain disorder. Strategies that include a plan to improve adherence to medical therapy through behavioral and educational techniques and innovative technology might contribute to improved adherence. All stakeholders must be involved in this effort, not just patients.

Developing and enhancing these collaborative and patient-centric approaches will increase self-monitoring and patient responsibility, and encourage behavior change.

**‘All-in’ strategy.** By continuing to use the latest technologies and connecting them to the range of stakeholders—physicians, nurses, pharmacists, payers—we will develop an all-inclusive adherence intervention strategy. All patients will be integrated, and all of them, and their family, will be provided with positive psychoeducational care and motivational counseling (Figure 5, page 34). In addition, such a support-based patient experience must be aligned with the work of clinical care providers. Compliance therapy and behavioral training, together with active patient engagement, can help improve insight, acceptance of treatment, and, over the long term, adherence.31,32

**References**

3. Crowe M, Wilson L, Linder M. Patients’ reports of the factors influencing medication adherence and other patient psychologic metrics (eg, activity, rest) through the wearable sensor patch and medical software application designed specifically for patient and physician use.

This technology could have huge potential in mental health care, where patients struggle with both adhering to their medication regimen and communicating with the health care team. Physicians could measure adherence when treating adults with schizophrenia, bipolar disorders, and major depressive disorder; flag those who are not adhering as having higher risk of disease progression and poorer outcome; and allow decisions to be made more quickly based on treatment need.
Adherence to medical therapy
continued from page 36


Clinical Point
One way around subterfuge is to employ an advanced technology solution, such as breath-based documentation or facial recognition.